TY  - JOUR
A1  - Schüler, Julia
A1  - Klingner, Kerstin
A1  - Bug, Daniel
A1  - Zöller, Caren
A1  - Maier, Armin
A1  - Dong, Meng
A1  - Willecke, Kerstin
A1  - Peille, Anne-Lise
A1  - Steiner, Eva
A1  - Landesfeind, Manuel
A1  - Copland, John A.
A1  - Siegers, Gabrielle M.
A1  - Haferkamp, Axel
A1  - Böhm, Katharina
A1  - Tsaur, Igor
A1  - Schneider, Meike
T1  - Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development
T2  - OncoTarget
N2  - Systemic treatment is necessary for one third of patients with renal cell carcinoma. No valid biomarker is currently available to tailor personalized therapy. In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas and determined serum levels of high mobility group B1 (HMGB1) protein under treatment with sunitinib, pazopanib, sorafenib, axitinib, temsirolimus and bevacizumab. Serum HMGB1 levels were significantly higher in a subset of the PDX collection, which exhibited slower tumor growth during subsequent passages than tumors with low HMGB1 serum levels. Pre-treatment PDX serum HMGB1 levels also correlated with response to systemic treatment: PDX models with high HMGB1 levels predicted response to bevacizumab. Taken together, we provide for the first time evidence that the damage associated molecular pattern biomarker HMGB1 can predict response to systemic treatment with bevacizumab. Our data support the future evaluation of HMGB1 as a predictive biomarker for bevacizumab sensitivity in patients with renal cell carcinoma.
KW  - HMGB1
KW  - renal cell carcinoma
KW  - damage associated molecular pattern
KW  - bevacizumab
KW  - VEGF
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/46539
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-465395
SN  - 1949-2553
N1  - All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
VL  - 9
IS  - 57
SP  - 30946
EP  - 30961
PB  - Impact Journals LLC
CY  - [s. l.]
ER  -